Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of antibody-based therapies for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The company operates within the biotechnology and pharmaceutical research industries, with an emphasis on immunology and precision-targeted biologics designed to address chronic inflammatory conditions.
The company’s primary revenue driver is research and development funding, as it does not currently generate product sales. Spyre Therapeutics is strategically positioned around a pipeline of monoclonal antibodies engineered to selectively target disease-driving pathways in the gastrointestinal tract. The company was originally founded as Aeglea BioTherapeutics in 2013 and later rebranded as Spyre Therapeutics following a strategic restructuring and pipeline redirection toward IBD-focused antibody therapeutics.
Business Operations
Spyre Therapeutics operates as a single-reportable segment focused on biologic drug discovery and clinical development. Its core business activities include antibody engineering, preclinical research, clinical trials, and regulatory advancement of investigational therapies. The company’s pipeline includes multiple antibody candidates targeting distinct inflammatory mechanisms relevant to IBD, with development programs spanning preclinical through mid-stage clinical trials.
Operations are primarily based in the United States, with research and development activities supported by external contract research organizations. Spyre Therapeutics controls its proprietary antibody engineering platforms and intellectual property while relying on third-party manufacturers for clinical-grade biologics. The company does not report material revenue from partnerships but has engaged in selective collaborations to support development and manufacturing activities.
Strategic Position & Investments
The strategic direction of Spyre Therapeutics centers on building a differentiated portfolio of targeted antibody therapies intended to improve efficacy and safety compared to existing systemic IBD treatments. Growth initiatives are focused on advancing multiple clinical candidates in parallel, enabling optionality across different biological targets and disease subtypes within IBD.
The company has invested heavily in expanding its pipeline through internal research and the acquisition of antibody assets during its corporate transformation. Notable investments include the prioritization of next-generation antibody formats designed for localized gut activity. Spyre Therapeutics does not disclose a diversified investment portfolio but concentrates capital on research, clinical trials, and regulatory readiness to support future commercialization or strategic partnerships.
Geographic Footprint
Spyre Therapeutics is headquartered in the United States, with its principal executive offices in Waltham, Massachusetts. Its operational footprint is primarily domestic, reflecting its focus on U.S.-based research, clinical development oversight, and regulatory engagement.
International presence is indirect and primarily related to clinical trial execution, with studies conducted across multiple regions through global contract research organizations. While the company does not maintain significant international offices, its clinical and regulatory strategy is designed to support potential future market entry in North America, Europe, and other major pharmaceutical markets.
Leadership & Governance
Spyre Therapeutics is led by an executive team with experience in biotechnology, drug development, and capital markets. The leadership emphasizes a focused R&D-driven strategy, disciplined capital allocation, and advancement of differentiated biologic therapies for underserved patient populations.
Key executives include:
- Cameron Turtle – Chief Executive Officer
- Mike Grey – Chief Financial Officer
- Kris Elverum – Chief Operating Officer
- David Lebwohl, M.D. – Chief Medical Officer
- David Weber, Ph.D. – Chief Scientific Officer
The board and management team collectively guide corporate governance, clinical strategy, and long-term value creation, with a stated focus on scientific rigor and patient-centered therapeutic development.